Figure 2 | Scientific Reports

Figure 2

From: A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment

Figure 2

Expression of RARs and effects of RARα antagonist (IRX6696) treatments in lung cancers. Basal expression profiles were independently displayed for RARα, RARβ and RARγ in human (panels a–c) and murine (panels d–f) lung cancer cells by real-time PCR assays. The chemical structure of IRX6696 is shown in panel (g). (h) Comparison of tumor growth in syngeneic lung cancer (344SQ cells in 129sv mice) treated with vehicle, anti-PD-L1, ATRA or in combination with anti-PD-L1, IRX6696 alone or in combination with anti-PD-L1. (i) immunohistochemical staining for CD3+ , CD8+ and CD4+ T cells are displayed in lung cancers treated with vehicle, anti-PD-L1, IRX6696 or in combination with anti-PD-L1 and (j) Immunofluorescent staining and quantifications of CD38 expression profiles are displayed.

Back to article page